Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (110 ops.)
Latest filing published 05 Jun 2026 for Denali Therapeutics Inc..
Filing timeline
BuySaleDavid P. Schenkein
Insider track record
Disclosed buys
2
Disclosed sells
110
Signal history
Closed purchases
Market purchases
2
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +10.5%Entry US$36.14 · Close at T+365 US$39.92
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
David P. Schenkein: trading record in brief
Filings by David P. Schenkein span 5 companies, the busiest being Agios Pharmaceuticals, Inc., Denali Therapeutics Inc. and bluebird bio, Inc. We count 223 filings; the first trade dates from 30 September 2013 and the latest from 3 June 2026.
Market trades split into 2 purchases (€308k) and 110 sales (€60.4M). Taken together, the sales exceed the purchases by €60.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 25 share grants and 71 option exercises.
On 5 June 2026 came the latest disclosure, a share grant in Denali Therapeutics Inc. The last insider purchase was made public on 15 November 2019, 2,535 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to David P. Schenkein
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations208 total
6,408 shares0Common StockSEC:0001578200-26-000004:0
155 shares0Common StockSEC:0001578200-26-000002:0
6,037 shares0Common StockSEC:0001714899-25-000138:0
166 shares0Common StockSEC:0001968202-25-000012:0
27,129 shares@ US$32.0910.8% of flowCommon StockSEC:0001714899-24-000219:1
32,312 shares@ US$32.8713.2% of flowCommon StockSEC:0001714899-24-000219:2
47,165 shares@ US$18.00100.0% of flowCommon StockSEC:0001714899-24-000219:0
3,388 shares0Common stockSEC:0001439222-24-000087:0
5,967 shares0Common StockSEC:0001714899-24-000136:0
11,858 shares@ US$33.600.8% of flowCommon stockSEC:0001439222-24-000042:1
57,471 shares@ US$31.643.8% of flowCommon stockSEC:0001439222-24-000042:2
57,471 shares@ US$34.894.2% of flowCommon stockSEC:0001439222-24-000042:3
11,858 shares@ US$31.646.2% of flowCommon stockSEC:0001439222-24-000042:0
47,731 shares@ US$33.0526.2% of flowCommon stockSEC:0001439222-24-000040:1
47,731 shares@ US$31.6425.1% of flowCommon stockSEC:0001439222-24-000040:0
20,411 shares@ US$31.6410.7% of flowCommon stockSEC:0001439222-24-000040:2
20,411 shares@ US$33.1911.2% of flowCommon stockSEC:0001439222-24-000040:3
42 shares0Common StockSEC:0001883850-24-000003:0
240 shares0Common StockSEC:0001104659-23-099992:0
4,975 shares0Common stockSEC:0001439222-23-000091:0
4,216 shares0Common StockSEC:0001714899-23-000096:0
16,363 shares@ US$9.052.4% of flowCommon stockSEC:0001439222-23-000058:0
16,363 shares@ US$22.850.8% of flowCommon stockSEC:0001439222-23-000058:1
20,000 shares@ US$9.053.0% of flowCommon stockSEC:0001439222-23-000056:0
20,000 shares@ US$22.150.9% of flowCommon stockSEC:0001439222-23-000056:1
25 of 208 declarations
